Investor Ideas #Potcasts 607, #Cannabis News and #Stocks
on the Move; (Nasdaq: $HITI), (CSE: $FFNT.C), (OTCQX: $AAWH), (TSXV: $KHRN.V), (CSE: $DELC.C)
Delta, Kelowna, BC,
October 7, 2021 (Investorideas.com Newswire) www.Investoride, as.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen
to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/100721-StocksToWatch.mp3
Read
this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/10071HITI-FFNT-AAWH-KHRN-DELC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas
potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In today’s podcast
we look at a few public company announcements.
4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF), a vertically-integrated,
multi-state cannabis operator and retailer, today announced that it has signed definitive
agreements on October 6, 2021, to acquire New England Cannabis Corporation, a
best-in-class cannabis cultivator, with state-of-the-art facilities based in
Holliston, Massachusetts. Upon closing, the Transaction is expected to be
significantly accretive to the Company's EBITDA expectations for 2022 and will
immediately scale 4Front's presence as a dominant wholesaler and producer in
the State.
Massachusetts'
competitive adult-use cannabis market is rapidly growing and 4Front has
already introduced
its full suite of popular brands in the State which have achieved wide-scale
consumer support. The Company expects the acquisition of NECC to significantly
expand 4Front's strategic position and enable broader market penetration of
4Front's diverse range of low-cost, high-quality products and brands.
As a technological
leader within the industry and one of the newest independent cannabis companies
in Massachusetts, NECC's fully operational 55,000 sq. ft. licensed cultivation
facility strengthens 4Front's expanding footprint in this important limited-license
state. The Transaction will more than double 4Front's total flower canopy in
Massachusetts to over 30,000 sq. ft, with further expansion potential for up to
an additional 10,000 sq. ft. of canopy, and will approximately triple 4Front's
kitchen, processing and distribution space. The NECC facility will supplement
the products sold through 4Front's existing "Mission" dispensaries
and further strengthen the Company's presence in the Massachusetts wholesale
market.
"The
acquisition of New England Cannabis reinforces our core thesis of bringing
scaled, low-cost production and operational depth to attractive, nascent,
adult-use cannabis markets" said Leo Gontmakher, Chief Executive Officer
of 4Front. "The addition of NECC's impressive operations will increase our
canopy, kitchen capacity, and add to our extraction capabilities overnight,
greatly bolstering our position in the Massachusetts market to become a leading wholesaler of our full
suite of products and brands. This acquisition firmly anchors our foothold in
the Northeast, and NECC's state-of-the-art facility will help to drive our
growth in the years ahead as we execute on our goal of achieving dominant
market share in every geography we operate. I look forward to working with
NECC's seasoned team and leveraging their extensive operational experience as
we continue to scale."
Ascend Wellness Holdings, Inc. (CSE: AAWH.U) (OTCQX: AAWH), a multi-state,
vertically-integrated cannabis operator, and Edie Parker, a luxury fashion
brand known for its vintage-inspired clutches and handbags, today announced the debut of Flower by Edie
Parker pre-rolls in Massachusetts. In May, AWH and Edie Parker announced an
exclusive wholesale licensing agreement to bring Flower by Edie Parker products
to emerging adult-use markets in Massachusetts and Illinois. The coveted West
Coast brand first expanded beyond California earlier in March by launching
sales in Colorado.
Flower by Edie
Parker is now available at AWH's flagship Boston location at 272 Friend St and
became available statewide via AWH's distribution network on October 3rd. By
early November, patients and consumers in Illinois will also be able to
purchase Flower by Edie Parker pre-rolls at all eight of AWH's retail
locations. Elegantly packaged and sold in new 'Best Buds' twin packs of 0.5
gram pre-rolls, customers can choose from three distinct offerings including:
●
Early Bird, a sativa product
featuring a light and creative flavor that pairs well with morning hike or
mid-afternoon coffee.
●
Happiest Hour, a hybrid product
that's party perfect, ideal for hanging with friends or a night out dancing.
●
Nightcap, an indica perfect for
evening or any relaxation ritual.
"Edie Parker's brand is known for its
elegant aesthetic and devotion to delivering top-notch cannabis products and
accessories," said AWH Founder and CEO Abner Kurtin. "We believe Edie
Parker will elevate and expand the selection at AWH stores, enticing new
customers and delighting returning ones. Bringing this exceptional West Coast
brand out East is part of our ongoing strategy of developing deeper
relationships with customers in our existing markets, and we are excited to
bring Edie Parker's products to this increasingly sophisticated audience."
In addition to debuting its pre-rolls in
Massachusetts and Illinois, Edie Parker will offer a curated assortment of the
brand's vibrant and artisanal cannabis
accessories wherever their products are sold and plan to launch a
number of brand activations at AWH stores over the next month. AWH pop-ups will include Edie Parker's
acclaimed branding featuring imagery, banners and whimsical activations similar
to the brand's most recent New York Fashion Week event.
"Our brand is all about celebrating
cannabis with others, and we are thrilled to share our distinctive line of
products with two new communities of consumers," said Brett Heyman,
Founder of Flower by Edie Parker. "The idea behind our Best Buds pre-rolls
is to share premium cannabis with your best bud. No matter the occasion, our
line of products was created to surprise and delight. The AWH team shares our
commitment to bringing fun yet polished cannabis experiences to the everyday
consumer, and our partnership enables us to show even more consumers how to be
loud and proud about their love for the plant."
A recent opinion article discussed the many
benefits of the Massachusetts’ cannabis model commenting that the state and how
other states are taking noticed as “Massachusetts has taken the lead by
developing a regulatory framework that protects both the state and consumers by
creating an environment that reflects a healthy balance between centralized
licensing and enforcement authority — housed in the Cannabis Control Commission
(CCC), and local autonomy in the selection and vetting of the participants and
applicable zoning enforcement.”
Khiron
Life Sciences Corp. (TSXV: KHRN)(OTCQX: KHRNF), a vertically integrated
international cannabis leader with core operations in Latin America and Europe,
announced that the Company presented results
from its first research study including 1,453 patients from Khiron-owned
Zerenia Clinics at the 29th International Pain Conference in Barranquilla,
Colombia, organized by ACED, the Colombian chapter of the International
Association for the Study of Pain (IASP).
The study, entitled "Prescription
patterns and clinical outcomes in a cohort of patients receiving progressive
therapy with cannabinoids for medical use in Colombia", is a longitudinal,
retrospective cohort study including 1,453 patients receiving treatment with
medical cannabis at Khiron-owned clinics in Colombia, Zerenia and ILANS.
The scope of research was to capture
patient-reported outcome measures (PROMS) and patient-reported experience
measures (PREMS) of general efficacy, adherence, and side effects of oral
formulations ranging in cannabinoid content for the treatment of different
health conditions with a diverse patient base over a twelve-month period.
The research protocol was reviewed and
approved by the Scientific Institutional Committee and the Research Ethical
Committee of the Universidad del Bosque, in Colombia, one of the leading
institutions on medical research in the region.
Demographic results reported most patients
were female (73%) with and average age of 59.3 years old, which is in strong
contrast with results arising from Project T21, the UK's first medical cannabis
registry Khiron Life Sciences has been supporting since its foundation in 2019.
Patients in the study were mainly diagnosed with chronic, non-cancer pain
(77%), followed by nausea and vomiting (8%), insomnia (6%), anxiety (5%),
spasticity and depression, among others and up to 68 % of patients had their
medical cannabis prescription cost covered by the Social Security in Colombia.
Study results show a patient-reported positive clinic response in more than 80%
of participants with only minor side-effects associated to the treatment.
"Scientific research and data are key
to convincing doctors and policy makers all over the world about the benefits
of medical cannabis to treat conditions that are prevalent in every society and
market we are targeting. After one year of compiling information and having
gone through a very detailed approval process, we are very proud to share the
results from this first-of-its-kind clinical study in Latin America with such a
significant patient base. This is just the beginning of our ongoing research
program. We are looking forward to sharing the outcomes of this first cohort
study with the international medical audience through peer-reviewed,
specialized publications so doctors all over the world can continue to drive
prescription growth safely and responsibly ", commented Alvaro Torres,
Chief Executive Officer and Director of the Company.
Delic
Holding Corp Inc. (CSE: DELC) (OTCQB: DELCF) announced that Delic Labs has applied for a
Health Canada 56 Research Exemption that would allow the scientists to perform
research and tests on a host of compounds outside of psychedelic mushrooms,
including MDMA and LSD. The lab currently holds a 56 Research Exemption for
chemistry analytics on psilocybin mushrooms.
Additionally, the lab has applied for a
Dealer's License and intends to eventually commercialize its psilocybin
research and associated intellectual property (IP) for medical and research
purposes. Some of the work would include researching extraction of
pharmaceutically relevant compounds from psychedelic mushrooms and turning
those extracts into medical products. Delic Labs will also synthesize
non-naturally occurring compounds as part of its ongoing med-chem pipeline.
Delic Labs is a federally authorized
psilocybin and cannabis research laboratory focused on extraction, analytical
testing, and chemical process development. Delic Labs serves as the engine for
the Delic platform, conducting research and developing innovative product lines
and intellectual property, including psilocybin vaporization technology for
future distribution across the Company's physical footprint and licensed
psychedelic wellness clinics in the United States.
Matt Stang, co-founder and CEO of Delic
Corp, stated, "Never before has a lab been authorized to test psychedelic
compounds such as MDMA and LSD with the opportunity to create new medicines for
the millions suffering from debilitating conditions like depression, anxiety, PTSD
and Parkinson's disease. Delic Labs is leading the way in psychedelic compound
testing and ensuring the safety and effectiveness of any treatments produced
using them, while also actively researching potential new medicines for the
market."
"Once we secure this 56 Research
Exemption together with the Dealer's License, Delic Labs will become the leader
in safety testing of psychedelic compounds to ensure the highest standards and
quality control," said Dr. Markus Roggen, co-founder of DELIC Labs.
"We will greatly expand our capabilities to work with other banned
substances, such as MDMA and LSD, along with psilocybin to develop new
psychedelic drugs for medical and research purposes. We believe we are on the
cusp of understanding the breadth of what is possible with psychedelics and
medicine."
Founded by Dr. Roggen, an award-winning
chemist, and UBC Professor, Dr. Glenn Sammis, Delic Labs supports the
psychedelic industry with high precision chemical analytics, metabolomic
identification and process optimization. Delic Labs is one of a handful of
licensed psilocybin research labs in Canada and has an aggressive plan to build
out a suite of novel compounds and delivery methods for the industry. Delic
Labs is also a leading cannabis analytical and research company boasting
clients that include some of the largest brands in the world.
High Tide Inc. (TSXV: HITI) (Nasdaq: HITI), a retail-focused cannabis
company enhanced by the manufacturing of proprietary and licensed consumption
accessories, announced that it is taking another step
towards solidifying itself as a major player within the global e-commerce
marketplace for hemp-derived CBD products, by entering into a definitive
agreement, pursuant to which High Tide will acquire 80% of Enigmaa Ltd.,
operating as Blessed CBD, for £9.06 Million, and will have a three-year option
to acquire the remaining 20% of Blessed at any time.
Founded in 2019
with its headquarters in Scotland, Blessed has quickly grown to become one of
the most popular brands for hemp-derived CBD products across the U.K.,
including CBD oils, creams, gummies, and capsules. In 2020 Blessed had almost 5
million site visits and an average order value of approximately £75. Blessed's
founder and Chief Executive Officer, Vithurs Thiru (known more commonly as
"V"), will join the High
Tide team as Senior Manager of Search (SEO) of the Company, and will help grow
High Tide's CBD business globally.
"I'm very
pleased to announce the addition of Blessed CBD, the U.K.'s top CBD brand as
designated by several prominent publications, into the High Tide family. We
continue to increase our online prowess by adding asset-light businesses to our
growing global e-commerce portfolio. Blessed is a fully direct-to-consumer platform
that generates industry-leading gross margins as well as EBITDA margins that
will continue to add to our consolidated margin profile," said Raj Grover,
President and Chief Executive Officer of High Tide. "This acquisition
marks our entry into the highly lucrative and rapidly-growing U.K. CBD space
which we expect to serve as a launching pad for High Tide to further penetrate
the E.U. market for hemp-derived CBD products, while also taking advantage of
cross-selling opportunities related to our in-house product lines. I have been
very impressed with the amazing business that V has been able to build within
just two years, and look forward to welcoming him and the rest of the Blessed
team into our company," added Mr. Grover.
"Blessed CBD
has experienced rapid growth and success from inception, and our goal is to
become the most sought-after CBD brand globally. Our team is super excited to
be joining hands with Raj, and by leveraging High Tide's existing resources and
reach, I couldn't be more excited about the future," said Vithurs Thiru,
CEO of Blessed. "I look forward to working with Raj and his team to
accelerate the digital presence of High Tide's brands, and to position High
Tide as one of the leading vertically-integrated cannabis companies in the industry.
This acquisition provides unparalleled opportunities for growth to serve our
current and future customers, expand into emerging new markets, and introduce
new products unmatched in quality," added Mr. Thiru.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the Investorideas.com website and that this podcast is not an
endorsement to buy products or services or securities. Investors are reminded
all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com
podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple
Podcasts) , Audible , Spotify, Tunein,
Stitcher, Spreaker.com, iHeartRadio ,
Google Podcasts and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through
Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com -
News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and
original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor
ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy, gaming and more. Investor Idea’s original branded content includes podcasts
and columns : Crypto
Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast
, Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye
Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
